Denosumab’s Therapeutic Effect for Future Osteosarcopenia Therapy: A Systematic Review and Meta-Analysis

I. Gusti Putu Suka Aryana, Sandra Surya Rini, Siti Setiati

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


Background: Osteosarcopenia, a combination of osteopenia/osteoporosis and sarcopenia, is a common condition among older adults. While numerous studies and meta-analyses have been conducted on the treatment of osteoporosis, the pharmacological treatment of osteosarcopenia still lacks evidence. Denosumab, a human monoclonal antibody, has shown encouraging results for the treatment of osteosarcopenia. Our systematic review and meta-analysis aimed to investi-gate the potential dual role of denosumab as an anti-resorptive agent and for other beneficial muscle-related effects in patients with osteosarcopenia, and to evaluate whether denosumab can be a treatment of choice compared to bisphosphonate. Methods: Relevant literature was collated from the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, and Google Scholar databases. The primary outcome was denosumab’s effect on lumbar spine bone mineral density (LS BMD), handgrip strength, and gait speed change. The secondary outcome was the effect of denosumab on appendicular lean mass (ALM). The outcomes were presented as mean dif-ference (MD). A random effects model was used in the analysis to represent the population. The risk of bias was assessed using funnel plots. Results: Out of the 3,074 studies found, four full-text studies met the inclusion criteria, including 264 and 244 participants in the intervention and control groups, respectively. Regarding a primary outcome, our meta-analysis showed that deno-sumab showed no significant differences in LS BMD and gait speed changes compared to other agents—MD=0.37, 95% confidence interval (CI),-0.35 to 0.79; p=0.09 and MD=0.11; 95% CI,-0.18 to 0.40; p=0.46, respectively. Denosumab had a significant effect on handgrip strength change compared to standard agents—MD=5.16; 95% CI, 1.38 to 18.94; p=0.007, based on the random effects model. Conclusions: Denosumab was better than bisphosphonate and placebo in improving muscle strength (handgrip strength). Therefore, denosumab may be favored in individuals with osteosarcopenia to improve muscular performance and reduce fall risk.

Original languageEnglish
Pages (from-to)32-41
Number of pages10
JournalAnnals of Geriatric Medicine and Research
Issue number1
Publication statusPublished - Mar 2023


  • Denosumab
  • Osteoporosis
  • Osteosarcopenia
  • Sarcopenia


Dive into the research topics of 'Denosumab’s Therapeutic Effect for Future Osteosarcopenia Therapy: A Systematic Review and Meta-Analysis'. Together they form a unique fingerprint.

Cite this